While this gastrointestinal adverse event can be uncomfortable, it is typically mild and temporary, resolving within a few weeks as the body adjusts to the medication
When nausea or appetite suppression diminishes after several weeks, some patients unconsciously increase portion sizes or return to high-calorie foods
Stopping and restarting these medications can also lead to obesity sarcopenia, where muscle that was lost as part of the overall weight loss is replaced by fat when the medication is stopped
Wear loose-fitting clothing to allow the injector easy access to the injection site
By stimulating glucose-dependent insulin secretion and suppressing glucagon production, they are a cornerstone of the treatment of type 2 diabetes (DM2), particularly in patients with a higher risk of cardiovascular disease ( This narrative review describes the complex interplay between GLP-1 signalling and intestinal inflammation, highlighting both the potential benefits and limitations of GLP1 RAs in IBD management, with a particular focus on their promising role in selected obese IBD patients